Larner Research Spotlight

Research at the Larner College of Medicine improves health outcomes, transforms lives, and addresses global health challenges. We share the stories of the questions, people, and innovations that are shaping a better, safer Vermont and planet.

The University of Vermont attained R1 status in February 2025, placing it in the top tier of research universities in the U.S. The university’s research profile in fiscal year 2024 attracted over $260 million in extramural support —more than doubling the university’s annual research funding in the last five years—and was led by the Larner College of Medicine which garnered over $100 million for biomedical, scientific and health related research. Scientific investigations at Larner resulted in improved treatments for sick infants and people with cancer, increased understanding of cardiovascular diseases and their impacts on dementia, new vaccines to combat infectious illnesses including Lyme disease, polio, the contagious respiratory virus RSV, and more.

UVM Cancer Center and UVM Children's Hospital Offer Promising Pediatric Oncology Trial

Fentanyl or Ketamine? UVM Researchers Join National Study Evaluating Pain Management for Traumatic Injury

R1 LARNER SPOTLIGHT: Cameron Cordero, CMB Ph.D. candidate, and Steven Roberts, Ph.D.

Larner Researchers Share Key Discoveries on Cardiovascular and Brain Health

R1 LARNER SPOTLIGHT: William Copeland, Ph.D.

R1 LARNER SPOTLIGHT: Mark Nelson, Ph.D.

UVM Achieves Prestigious Carnegie R1 Designation, Joining Highest Level of U.S. Research Institutions

R1 SPOTLIGHT: Mary Cushman – at the Forefront of Stroke and Brain Health Research

R1 SPOTLIGHT: Sean Diehl – Innovative Research that Advances RSV Prevention

Investigating Brain Health and Dementia

Spider Brain Research Leads VT Neuroscientists to Groundbreaking Alzheimer’s Discovery

Larner Scientist Maps Fruit Fly Brain

UVM at the Forefront of Stroke and Brain Health Research